Information Provided By: 
Fly News Breaks for March 23, 2015
RHHBY, BIIB, LLY
Mar 23, 2015 | 08:46 EDT
Cowen raised its price target on Eli Lilly (LLY) to $85 from $78 after Biogen (BIIB) released data last week on its Alzheimer's drug, BIIB-037. While Cowen acknowledged Biogen's data was the best the firm has seen to date, the firm also said Lilly leads by a "considerable margin" in terms of development timing for its drug solanezumab over competitors Biogen and Roche (RHHBY). Cowen forecast sales of $500M in 2020 for solanezumab and reiterated its Outperform rating on Eli Lilly shares.
News For LLY;BIIB;RHHBY From the Last 2 Days
BIIB
Apr 25, 2024 | 04:58 EDT
BIIB
Apr 24, 2024 | 16:14 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
BIIB
Apr 24, 2024 | 13:04 EDT
BIIB
Apr 24, 2024 | 08:50 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
BIIB
Apr 24, 2024 | 06:50 EDT
BIIB
Apr 24, 2024 | 06:48 EDT
RHHBY
Apr 24, 2024 | 06:33 EDT
RHHBY
Apr 24, 2024 | 06:30 EDT
